Pharmaceuticals

European approval for Bavarian Nordic's pediatric mpox vaccine is a critical health breakthrough and a masterclass in strategic market positioning.

X4 Pharmaceuticals secures a key European approval and overhauls its pivotal trial, signaling a major strategic shift backed by a newly extended cash runway.

Zentalis Pharmaceuticals is pursuing a dual strategy for its ovarian cancer drug, azenosertib, aiming for fast market entry while securing long-term validation.

With $911M in the bank, Relay Therapeutics is aggressively advancing its precision drug zovegalisib, targeting both breast cancer and rare vascular anomalies.

With its lead obesity drug in late-stage trials and a Novo Nordisk veteran newly hired, Structure Therapeutics is making a calculated play for the oral GLP-1 crown.

With a $250M decision pending and a major acquisition closing, Zymeworks is betting its future on a radical pivot to a diversified, revenue-generating model.

With late-stage trials underway and a cash runway into 2030, Trevi Therapeutics is accelerating its mission. But what does this mean for millions of unseen sufferers?

With a $215M war chest and a runway into 2028, Corvus Pharmaceuticals is aggressively advancing its lead drug, soquelitinib, across cancer and immune diseases.

With a Q3 FDA submission for its novel epilepsy drug azetukalner imminent, Xenon leverages a massive cash runway to expand into neuropsychiatry and pain.

Biotech firm MetaVia reports progress on its obesity drug DA-1726, with patients reaching high doses. Promising early data sets the stage for a pivotal Q4 readout.

Amphastar beats Q2 estimates with new drug sales, but a deeper look reveals pricing pressure, rising costs, and a high-stakes bet on its pipeline.

A new Health Canada approval for Regeneron's Libtayo offers a breakthrough for high-risk skin cancer patients and a strategic win for the company.

A startup led by ex-Novo Nordisk execs plans a reverse takeover to fund its made-in-Canada generic Ozempic, aiming to disrupt a C$3.5B market.

With new patents and a $300M war chest, Beren Therapeutics nears an FDA decision for its NPC drug. But can its public benefit model survive the high-risk biotech gauntlet?

Facing Nasdaq pressure, Barinthus Bio advances its Clywedog merger and pivotal celiac disease trial, with key data expected in Q4 2026.

vTv Therapeutics is nearing a critical milestone with its oral drug for Type 1 diabetes. Can it solve a deadly problem while navigating the financial tightrope?

A critical safety milestone for PepGen’s PGN-EDODM1 offers a glimmer of hope for myotonic dystrophy patients and highlights a novel strategy in a competitive field.

With the launch of its TED drug Lumvoa, Viridian Therapeutics steps into the commercial ring. But can early momentum and a deep pipeline justify the cost?

With nearly $800M in cash, Immunovant is all-in on a single drug, IMVT-1402. Can its ambitious six-front clinical strategy justify the burn and win the race?

With a 32% jump in royalty revenue and a game-changing acquisition, Ligand Pharmaceuticals solidifies its market dominance. But is the growth sustainable?